About Archemix
Archemix was a Healthcare company based in San Francisco (United States) founded in 2000. It develops aptamer therapeutics for rare hematological diseases. It operates on a B2B model. Archemix has raised $101.75 million across 2 funding rounds from investors including Atlas Venture, US Trust and Highland Capital Partners. The company is recorded as dissolved. Its focus areas include Biotechnology, Therapeutics and Rare Diseases. Its legal entity is ARCHEMIX CORP. Its competitors include Editas Medicine, GBT and LogicBio; 3 of its 3 listed competitors have raised funding.
Company details
Archemix, founded in 2000 in San Francisco, United States, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and rare diseases. Develops aptamer therapeutics for rare hematological diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Website archemix.com
- Legal Name Archemix Corp
- Total Equity Funding$101.75M (USD)
in 2 rounds
- Latest Funding Round$50M (USD), Series B
Apr 2004
- InvestorsAtlas Venture
& 8 more
Funding Insights of Archemix
Archemix has successfully raised a total of $101.75M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in April 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $101.75M
- Total Rounds 2
- Last Round Series B — $50M
- First Round $51.75M
(Aug 2002)
- Investors Count 9
All 2 funding rounds of Archemix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2004 | $50M | Series B | – | Highland Capital Partners | |
| Aug 2002 | $51.75M | Series A | – | Atlas Venture, Prospect Venture Partners |
9 investors in total: 9 institutional.
Investors in Archemix
Archemix has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Atlas Venture, US Trust and Highland Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and entrepreneur support services. | hcp.com | |||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
| carecapital.com | ||||
| mdscapital.com | ||||
| poscobioventures.com | ||||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Wealth management firm | 1853 | ustrust.com | New York, United States |
Investor details for Archemix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Archemix
3 dated milestones of Archemix across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Archemix is founded.
- Funding First funding round of $51.8M.
- Funding Latest funding round, Series B, of $50.0M.
Competitors of Archemix
Archemix has 3 listed competitors in our database, 3 of them funded. They include Editas Medicine, GBT and LogicBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. | |
| gbt.com | 2011 | San Francisco, United States | $177.4M | 457 | Small molecules are developed for sickle cell disease treatment. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. |
Detailed competitors of Archemix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Archemix (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Archemix
Archemix was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Archemix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Archemix is a funded company, having raised a total of $101.75M across 2 funding rounds to date. The company's 1st funding round was a Series A of $51.75M, raised on Aug 2002.
Archemix, founded in 2000 in San Francisco, United States, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and rare diseases. Develops aptamer therapeutics for rare hematological diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Archemix's top competitors include GBT, Editas Medicine and LogicBio.
Archemix has 9 investors. Key investors include Atlas Venture, US Trust, Highland Capital Partners, Prospect Venture Partners, and Rho Capital Partners.
Archemix operates through Archemix Corp.